Background: The once-daily protease inhibitor atazanavir (ATV) boosted with low-dose ritonavir (RTV) and combined with other antiretrovirals is approved for the treatment of HIV-1 infection. Cobicistat (COBI), an alternative booster with more selective CYP3A inhibition but no antiretroviral activity or CYP induction, has similar pharmacoenhancing activity as RTV. A Phase III trial has demonstrated comparable efficacy and safety of ATV 300 mg + COBI 150 mg relative to ATV 300 mg + RTV 100 mg (85% vs 87% virologic suppression, respectively). To reduce pill and prescription burden, a fixed-dose combination (FDC) of ATV/COBI has been developed. Because ATV is recommended to be taken with food, which enhances ATV bioavailability and reduces pharmacokinetic variability, we assessed the bioequivalence of ATV and relative bioavailability of COBI in an FDC vs ATV and COBI coadministered individually after a light meal. Methodology: This randomized, open-label, cross-over study in 64 healthy subjects assessed 48-hour ATV and COBI plasma concentration-time profiles after single doses of an FDC of ATV 300 mg/COBI 150 mg or ATV 300 mg and COBI 150 mg co-administered as individual agents (NCT01837719). Treatments were administered after a light meal and followed by a 7-day washout between each period. Pharmacokinetic (PK) parameters assessed were maximum plasma concentration (Cmax), area under the concentration-time curve to infinity and to the last time point with measurable able concentration AUC(0-T), and concentration at 24-hour post-dose (C24) for ATV. Bioequivalence for ATV was established if the 90% confidence intervals (CIs) for the FDC vs individual administration geometric mean ratios (GMRs) fell within the predefined limits of 0.80-1.25 for all PK parameters. Results: All ATV PK parameter GMR 90% CIs fell within the predefined limits indicating bioequivalence of the FDC to ATV 300 mg and COBI 150 mg coadministered individually (Table). Although not prespecified, COBI in the FDC also met the criteria for bioequivalence to coadministration of the individual agents. Not unexpectedly with ATV, 5 subjects treated per protocol had total bilirubin elevations (1.2-2.1 × ULN), which were all improving or had resolved by study discharge. Conclusions: ATV and COBI administered in an FDC is bioequivalent to coadministration of the individual agents under fed conditions. A single dose of ATV 300 mg and COBI 150 mg was safe and well tolerated when administered either as the FDC or as individual agents.